Neurocrine Biosciences (NBIX) and Abbott Labs (ABT) announce a global agreement to develop and...


Neurocrine Biosciences (NBIX) and Abbott Labs (ABT) announce a global agreement to develop and commercialize elagolix for treatment of endometriosis. NBIX shares +14.3%, ABT -0.2% premarket. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs